TY - JOUR
AU - A. Kline
AU - J. M. Williams
AU - M. L. Steinberg
AU - D. Mattern
AU - M. Chesin
AU - S. Borys
AU - V. Chaguturu
A1 - 
AD - Rutgers-Robert Wood Johnson Medical School, Department of Psychiatry, 317 George Street, New Brunswick, NJ 08901, United States. Electronic address: klinean@rwjms.rutgers.edu.;Rutgers-Robert Wood Johnson Medical School, Department of Psychiatry, 317 George Street, New Brunswick, NJ 08901, United States. Electronic address: williajm@rwjms.rutgers.edu.;Rutgers-Robert Wood Johnson Medical School, Department of Psychiatry, 317 George Street, New Brunswick, NJ 08901, United States. Electronic address: steinbml@rwjms.rutgers.edu.;Rutgers-Robert Wood Johnson Medical School, Department of Psychiatry, 317 George Street, New Brunswick, NJ 08901, United States. Electronic address: dm1215@rwjms.rutgers.edu.;William Paterson University, 300 Pompton Road, Wayne, NJ 07470, United States. Electronic address: mschesin@gmail.com.;New Jersey Department of Human Services, Division of Mental Health and Addiction Services, 222 S. Warren St., PO Box 700, Trenton, NJ 08625-0700, United States. Electronic address: Suzanne.borys@dhs.nj.gov.;Rutgers-Robert Wood Johnson Medical School, Department of Psychiatry, 317 George Street, New Brunswick, NJ 08901, United States. Electronic address: chagutvk@rwjms.rutgers.edu.
AN - 37003539
BT - J Subst Use Addict Treat
C5 - Opioids & Substance Use;Healthcare Disparities
DA - Jun
DO - 10.1016/j.josat.2023.209028
DP - NLM
ET - 20230331
JF - J Subst Use Addict Treat
LA - eng
PY - 2023
SN - 2949-8767 (Print);2949-8759
SP - 209028
ST - Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone
T1 - Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone
T2 - J Subst Use Addict Treat
TI - Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone
U1 - Opioids & Substance Use;Healthcare Disparities
U3 - 10.1016/j.josat.2023.209028
VL - 149
VO - 2949-8767 (Print);2949-8759
Y1 - 2023
ER -